Press release - 13/08/2021 Paradigm shift in immunology 'Adaptive Tolerance' balances autoimmune reaction Immunologists at Ulm University and its Medical Centre have developed a new model that could revolutionise the treatment of autoimmune disease as well as vaccine development. As 'Adaptive Tolerance' demonstrates, autoreactive antibodies are by no means disease drivers which a healthy organism swiftly eliminates. Rather, they trigger the formation of a class of antibodies that protect the body's own structures. https://www.gesundheitsindustrie-bw.de/en/article/press-release/paradigm-shift-immunology-adaptive-tolerance-balances-autoimmune-reaction
Article - 03/12/2010 Review: Science meets Business Day 2010 (part II) How can plant physiologists and seed developers work together to achieve an understanding of the processes happening in the germinating plant embryo in order to improve the seed quality of sugar beet? How can virologists find new ways to switch off the flu virus and develop a marketable vaccine in cooperation with industrial partners?https://www.gesundheitsindustrie-bw.de/en/article/news/review-science-meets-business-day-2010-part-ii
Microfluidics in medical technology - 24/03/2021 Ultra-compact: valves with shape memory actuators Karlsruhe-based company memetis shows that this is possible. Intelligent components for controlling fluids open up huge potential in the medical technology and biotechnology sectors - from vaccine development and cell line analysis to drug research and point-of-care solutions.https://www.gesundheitsindustrie-bw.de/en/article/news/ultra-compact-valves-shape-memory-actuators
Press release - 20/10/2020 EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. https://www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
Article - 27/07/2016 “Open science“ – a successful recipe for combating viruses Danger identified, danger averted – the better the dynamic changes of the viral genome are understood, the better the spread of the pathogens can be predicted, thus enabling more efficient countermeasures to be taken. A team of researchers from Tübingen and Seattle is developing an open source online platform that maps the evolution of viruses and identifies dangerous developments.https://www.gesundheitsindustrie-bw.de/en/article/news/open-science-a-successful-recipe-for-combating-viruses
Article - 14/03/2018 Patent versus publication: setting up start-ups in the sciences When it comes to universities as start-up incubators, the Massachusetts Institute of Technology (MIT) in the USA is often used as a prime example of entrepreneurial impact. Well over 100 high-tech spin-offs have been set up in the vicinity of the renowned university. Many German universities also offer attractive conditions for scientists with an entrepreneurial spirit. https://www.gesundheitsindustrie-bw.de/en/article/news/patent-versus-publication-setting-up-start-ups-in-the-sciences
Material research - 25/05/2020 Reaching up into weightlessness – a start-up that enables commercial research experiments in space Yuri, a start-up company founded in 2019 in the Lake Constance area, is aiming high. The company’s mission is to enable microgravity research into the development of materials, new medicines and vaccines, including research opportunities on the International Space Station (ISS). Yuri’s tailor-made solutions are faster and more affordable than previous space research missions.https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-up-into-weightlessness-a-start-up-enables-commercial-research-experiments-in-space
Article - 13/07/2015 CureVac and Boehringer Ingelheim - two strong partners forge cancer immunotherapy alliance Two German companies have teamed up to become a driving force in the immunotherapy of lung carcinomas. CureVac GmbH from Tübingen and Boehringer Ingelheim are working together on the development of a therapy for non-small cell lung cancer using CureVac’s vaccine CV9202. The drug is based on messenger RNA and will be used in combination with other therapies with the goal of fighting the tumour on several fronts.https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-and-boehringer-ingelheim-two-strong-partners-forge-cancer-immunotherapy-alliance
Press release - 03/11/2015 CureVac raises $110 Million in a private placement CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
Article - 14/07/2009 Tiny particles are a weapon against tumours Prostate carcinoma is one of the most common malignant diseases claiming more than 84000 lives per year in the EU and the United States. In cooperation with the University of Constance the Thurgau Biotechnology Institute BITg is working on ways to remove prostate carcinomas and other tumours that are difficult to treat by using tiny particles made of biologically degradable polyester. Prof. Dr. Marcus Groettrup and his team of researchers have…https://www.gesundheitsindustrie-bw.de/en/article/news/tiny-particles-are-a-weapon-against-tumours
Dossier - 13/04/2015 Boosting the immune system can improve cancer prevention and treatment The activation of the body’s immune system to fight cancer is not only a promising therapeutic concept, but is already used in medical practice. The first immunotherapies have been approved and many more are either in the experimental stages or already undergoing clinical testing. Vaccines to prevent certain types of cancer are already being used successfully around the world.https://www.gesundheitsindustrie-bw.de/en/article/dossier/boosting-the-immune-system-can-improve-cancer-prevention-and-treatment
Article - 12/02/2008 Hermann Bujard - a passionate basic researcher As one of the people who initiated the establishment of EMBL and in his role as founding director of the ZMBH Hermann Bujard has made a considerable contribution to the transformation of Heidelberg into a leading location for molecular and biological research in Germany. As the director of EMBO Bujard is now promoting the development of molecular biosciences across Europe.https://www.gesundheitsindustrie-bw.de/en/article/news/hermann-bujard-a-passionate-basic-researcher
Article - 17/05/2013 Dengue fever, the neglected infectious disease Dengue fever is the most common infectious disease transmitted by mosquitoes. The disease is spreading in Europe and Germany, an upward trend that is due to increased long-distance travel. There are no specific drugs or vaccine for dengue, which is why an international research network has been established to improve the management of the disease. The consortium is coordinated by the Department of Tropical Medicine at Heidelberg University.https://www.gesundheitsindustrie-bw.de/en/article/news/dengue-fever-the-neglected-infectious-disease
Article - 19/04/2010 Natural antibodies to treat Alzheimer’s Alzheimers disease is characterised by changes in the substance and structure of the brain that are caused by the depositing of protein plaques in the brain. Prof. Michael Przybylski and his team of researchers at the University of Constance have deciphered the structure of the site where mouse antibodies attach to the plaques subsequently causing them to dissolve. These findings will now be used to identify the binding structure of a component…https://www.gesundheitsindustrie-bw.de/en/article/news/natural-antibodies-to-treat-alzheimer-s
Article - 22/08/2016 Ad-O-Lytics – a new biotech start-up from Ulm A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
Press release - 06/10/2008 Harald zur Hausen wins Nobel Prize in Medicine Harald zur Hausen the long-time chairman and scientific director of the German Cancer Research Centre DKFZ a member of the Helmholtz Society discovered that human papillomaviruses HPV lead to cervical cancer. His discovery led to the development of a vaccine for cervical cancer which is the third most frequent type of cancer in women.https://www.gesundheitsindustrie-bw.de/en/article/press-release/harald-zur-hausen-wins-nobel-prize-in-medicine
Article - 15/12/2009 Arming the immune system against cancer The theory that immune cells are able to attack tumours has long been a theory with only a minority of supporters. However, this theory is currently experiencing a renaissance. In the future, it might even be possible to specifically alter T-lymphocytes in order to improve their ability to identify and destroy certain tumour types. Prof. Dr. Hanspeter Pircher and his team at the Freiburg University Medical Centre are focusing on the development…https://www.gesundheitsindustrie-bw.de/en/article/news/arming-the-immune-system-against-cancer
Peptide-based COVID-19 vaccine - 21/04/2022 CoVac-1: T-cell activator against COVID-19 Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
Article - 10/05/2008 Straight questions and answers The 14th Biotech Finance Forum offered selected biotechnology and medical technology companies from all over Europe the opportunity of an exclusive meeting with internationally operative investors from the venture capital VC scene. https://www.gesundheitsindustrie-bw.de/en/article/news/straight-questions-and-answers
Review article (new edition) - 08/07/2020 Immunology – at the forefront of medical progress Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.https://www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress
Article - 01/03/2008 New active substance against hepatitis B Scientists at the University Hospital in Heidelberg have discovered a hepatitis B virus peptide that can prevent viral infections in a mouse model. A team led by Professor Stephan Urban is developing a virus blocker against hepatitis B infections. Despite vaccinations every year about 750000 people die from the consequences of hepatitis B infections.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-active-substance-against-hepatitis-b
Article - 11/06/2019 New pathogens in beef and cow's milk contributing to the risk of cancer A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
Article - 28/02/2011 Development of food allergies Allergic reactions to certain types of food can, in extreme cases, lead to life-threatening anaphylactic shock. People with peanut allergies are particularly at risk. Allergic reactions can also gradually develop into chronic intolerances such as coeliac disease, for example. The causes of food allergies nearly always originate in early childhood. https://www.gesundheitsindustrie-bw.de/en/article/news/development-of-food-allergies
Press release - 16/04/2008 Effective Cancer Immune Therapy Through Order in the Blood Vessels Researchers at the German Cancer Research Center have discovered a key molecule that is responsible for the immature structure of blood vessels in malignant tumors. If this molecule is switched off in mice vessels normalize so that immune cells are better able to get to the tumor tissue.https://www.gesundheitsindustrie-bw.de/en/article/press-release/effective-cancer-immune-therapy-through-order-in-the-blood-vessels
Plant breeding - 19/11/2018 Tobacco for health Plants can be used as biofactories to produce valuable active ingredients such as proteins, antibodies, dyes or vaccines. A project called Newcotiana aims to re-position the existent tobacco industry infrastructure. The project partners, including Prof. Dr. Holger Puchta from the Karlsruhe Institute of Technology, use modern breeding methods to develop tobacco varieties with new capabilities.https://www.gesundheitsindustrie-bw.de/en/article/news/tobacco-for-health